Acquisitions and Other Strategic Transactions - BioTrace (Details) - BioTrace $ in Millions |
Oct. 03, 2022
USD ($)
item
|
|---|---|
| Asset Acquisition [Line Items] | |
| Purchase price | $ | $ 2.5 |
| Number of annual payments | item | 6 |
| Minimum | |
| Asset Acquisition [Line Items] | |
| Net sales revenue (as a percent) | 5.00% |
| Maximum | |
| Asset Acquisition [Line Items] | |
| Net sales revenue (as a percent) | 10.00% |
| Developed technology | |
| Asset Acquisition [Line Items] | |
| Amortization period | 10 years |
| X | ||||||||||
- Definition Represents the number of contingent annual payments under the asset acquisition agreement. No definition available.
|
| X | ||||||||||
- Definition Percentage of net sales revenue for contingent consideration from asset acquisition. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|